Definium Therapeutics (DFTX) Shares Outstanding (Diluted Average) (2020 - 2025)

Definium Therapeutics (DFTX) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $89.3 million in Q4 2025.

• Quarterly Shares Outstanding (Diluted Average) rose 26.78% year-over-year to $89.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $89.3 million (up 26.78% YoY) and the FY2025 annual result came in at $89.3 million, up 26.78% from the prior year.
• Shares Outstanding (Diluted Average) advanced to $89.3 million in Q4 2025 per DFTX's latest filing, from $70.5 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $420.1 million in Q3 2021 and bottomed at $27.4 million in Q4 2021.
• The 5-year median for Shares Outstanding (Diluted Average) is $39.7 million (2023), against an average of $110.1 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) plunged 93.2%; it then jumped 102.01% in 2024.
• Tracing DFTX's Shares Outstanding (Diluted Average) over 5 years: stood at $27.4 million in 2021, then climbed by 12.71% to $30.9 million in 2022, then grew by 26.9% to $39.2 million in 2023, then surged by 79.94% to $70.5 million in 2024, then grew by 26.78% to $89.3 million in 2025.
• Per Business Quant, the three latest DFTX Shares Outstanding (Diluted Average) figures stand at $89.3 million (Q4 2025), $70.5 million (Q4 2024), and $80.2 million (Q3 2024).

Peer Comparison